バイオ医薬品

The Frontline of Spatial Biology and Liquid Biopsy at AACR 2026

2026.04.10
The AACR Annual Meeting, organized by the American Association for Cancer Research (AACR), is one of the worl… 黒澤伸行

Webinar Announcement: What is 3D Bioprinting That Transforms Vascular Model Reproducibility?

2026.04.10
Atherosclerosis progresses through a complex interplay between vascular geometry, blood flow dynamics, and endothelial biological res… 黒澤伸行

Introductory Knowledge of Intellectual Property in Life Sciences – The Essential Relationship Between Medicines and Patents

Vol. 10：Shutting Out Gx – Evolving Originator Patent Strategies-

2026.03.31
n Japan, the share of generic drug usage had traditionally been quite low. In 2005, generic share by volume was around 30% , significantly lower compared to approximately 90% in the Un… 黒澤伸行

Vol. 9: Wait what? Generic Drugs can be Denied Approval?!—What is Patent Linkage?－

2026.03.01
Did the title “Generic Drugs Can Be Denied Approval?!” surprise you?This topic is connected to the so-called “patent linkage” system that I briefly mentioned inVol. 5,“Do The… 黒澤伸行

Vol. 8: Monetization from Litigation to Licensing: The Opdivo vs. Keytruda Patent War

2026.01.30
Last time, we discussed Patent Invalidation Trials as the most powerful counteraction when accused of patent infringement. Filing a lawsuit against acts that infringe a patent right, and the other party respo… 黒澤伸行

Vol. 7: Wait what? You can squash a patent? – How to Defeat Patents That Block Advances in Life Science Business-

2025.11.30
Last time, we discussed patent litigation. The most powerful counteraction when accused of patent infringement is to “squash the patent” — that is, to invalidate it. If the patent can be invalidated, the rights that … 黒澤伸行

Vol. 6: Sued for Patent Infringement? – Here’s How the Litigation would Unfold –

2025.11.01
Unlike the United States—a country known for its litigious culture – Japan sees relatively few patent lawsuits. However, the situation is somewhat different in the life sciences sector. In May of this year, a high-profile p… 黒澤伸行

Vol. 5: Do they really creep in? – Development schedules of Generics and Biosimilars

2025.09.30
This time, we are going to talk about generic drugs and biosimilars. These days in Japan we don't hear the word "zoro", but up until about 20 years ago, generic drugs were commonly referred to as "zoro." The word “zoro” stems … 黒澤伸行

Vol. 4: What do you mean “patents can be extended”? – Patent Term Extension: A special system for pharma–

2025.09.01
Last time, we discussed how to obtain a patent, following the process from application to obtaining a patent. I touched on the length of a patent term at the end. Do you remember how long a patent term was? The answer is 20… 黒澤伸行

Vol. 3: Shall we talk about how to obtain a patent? – Process flow from patent application to obtaining a patent –

2025.07.31
So far, we’ve explored the medicine classification and patents (Vol. 1), and the reasons why Medicines and Patents are inseparable (Vol. 2). In this volume, the spotlight fa… 黒澤伸行